0001144204-12-000607.txt : 20120105 0001144204-12-000607.hdr.sgml : 20120105 20120105104801 ACCESSION NUMBER: 0001144204-12-000607 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20111231 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120105 DATE AS OF CHANGE: 20120105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bohai Pharmaceuticals Group, Inc. CENTRAL INDEX KEY: 0001443242 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980588402 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53401 FILM NUMBER: 12509620 BUSINESS ADDRESS: STREET 1: C/O YANTAI BOHAI PHARMACEUTICALS GROUP STREET 2: NO. 9 DAXIN ROAD, ZHIFU DISTRICT CITY: YANTAI, SHANDONG PROVINCE STATE: F4 ZIP: 264000 BUSINESS PHONE: 86-535-6763559 MAIL ADDRESS: STREET 1: C/O YANTAI BOHAI PHARMACEUTICALS GROUP STREET 2: NO. 9 DAXIN ROAD, ZHIFU DISTRICT CITY: YANTAI, SHANDONG PROVINCE STATE: F4 ZIP: 264000 FORMER COMPANY: FORMER CONFORMED NAME: Link Resources Inc. DATE OF NAME CHANGE: 20080818 8-K 1 v243855_8k.htm FORM 8-K Unassociated Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported): January 5, 2012 (December 31, 2011)

Bohai Pharmaceuticals Group, Inc.
(Exact name of registrant as specified in its charter)

Nevada
 
000-53401
 
98-0697405
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)


c/o Yantai Bohai Pharmaceuticals Group Co. Ltd.
No. 9 Daxin Road, Zhifu District
Yantai, Shandong Province, China 264000
(Address of principal executive offices)

Registrant’s telephone number, including area code: +86(535)-685-7928

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 

Item 1.01 Entry into a Material Definitive Agreement

On January 5, 2010, Bohai Pharmaceuticals Group, Inc. (the “Company”) entered into a Securities Purchase Agreement with certain accredited investors, for which Euro Pacific Capital, Inc. (“Euro Pacific”) is acting as representative, whereby the Company issued two-year convertible notes in the aggregate amount of $12 million (collectively, the “Notes”) and warrants to purchase shares of the Company’s common stock.  As of the date of this Report, there is currently $10.5 million due under the Notes and the current maturity date of the Notes is January 5, 2012.

On December 31, 2011, the Company entered into an amendment to the Notes with Euro Pacific as representative of the Investors (the “Amendment”) which: (i) extended the maturity date of the Notes from January 5, 2012 to April 5, 2012 (such extra three month period, the “Extended Period”); and (ii) increased the interest rate on the Notes to an annual rate of 12% (or 3% for the Extended Period).  A copy of the Amendment is attached hereto as Exhibit 4.1.  The description of the Amendment is qualified in its entirety by reference to Exhibit 4.1.

Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On December 31, 2011, Mr. Gene Hsiao submitted to the Board of Directors of the Company his resignation as a director of the Company and the Chief Financial Officer of the Company, which resignation became effective on December 31, 2011.  Mr. Hsiao’s resignation was for personal reasons and not as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.  Mr. Hsiao noted in his resignation letter that his decision to resign was difficult as working at the Company has been a great experience for him for which he is extremely grateful.  Mr. Hsiao wished the Company every success in the future and thanked the Company’s Chairman and Chief Executive Officer, Mr. Hongwei Qu, for the opportunities Mr. Hsiao was given during his tenure with the Company.

Mr. Qu noted his thanks to Mr. Hsiao for his service to the Company over the past one and one-half years.  Mr. Qu further noted that the officers and employees of the Company have enjoyed working with Mr. Hsiao and wish him the best in his future endeavors.

The Company is in the process of identifying a qualified candidate to fill the vacancy created by Mr. Hsiao’s resignation.

Item 8.01   Other Information

Fiscal Second Quarter 2012 Revenue Guidance and other information

 
The Company is hereby publishing its preliminary gross revenue guidance for the second quarter of fiscal year 2012 ended December 31, 2011 in the range of $35.7 million to $40 million which, if achieved, would represent year-over-year quarterly growth of approximately 60.8-80.2%.  The Company expects that this revenue growth were driven by a combination of the acquisition of Yantai Tianzheng Pharmaceuticals Co., Ltd in the first quarter of fiscal 2012 and an increase in sales of the Company’s key products  In addition, the Company expects revenue growth to continue during the second half of fiscal 2012.  During recent fiscal quarters, the Company has been generating net operating cash flow approximately in the range of $3 to 4 million per quarter. 
 
The Company currently produces 19 varieties of approved traditional Chinese herbal medicines.  Of these 19 products, 12 are prescription drugs and 7 are over the counter (or OTC) products.  By the end of the fiscal 2011, the Company added more than 200 level 2 hospitals and more than 10 new drug store chains to its national network of retail locations in China currently selling its key product, Lung Nourishing Syrup.  As a result, the Company now sells Lung Nourishing Syrup in more than 1,600 level 2 hospitals and more than 36 drug store chains across China.
 
 
 

 
 
In addition, the Company continues to explore strategic opportunities in its continuing efforts to grow its business and bring value to shareholders, including operational and financing opportunities.

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

This Current Report on Form 8-K of Bohai Pharmaceuticals Group, Inc. (the "Company") contains, or may contain, statements that are not historical facts and are therefore "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, beliefs, expectations and intentions and other statements identified by words such as “guidance,” "projects," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan," or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results, including, without limitation, future financial results and results regarding the Company's strategic initiatives and the Company’s prospects for growth, may differ significantly from those set forth in the forward-looking statements.  These forward -looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company does not undertake any obligation to update any forward- looking statement, except as required under applicable law.

Item 9.01  Financial Statements and Exhibits

(d) Exhibits

 
4.1
Amendment to Convertible Notes
 
17.1
Letter, dated December 31, 2011, from Gene Hsiao to the Company.
 
 
 

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

January 5, 2012
Bohai Pharmaceuticals Group, Inc.
   
 
By:  
/s/ Hongwei Qu
   
Name:  Hongwei Qu
   
Title:    Chief Executive Officer
 
 
 
 

 
 
EX-4.1 2 v243855_ex4-1.htm AMENDMENT TO CONVERTIBLE NOTES Unassociated Document
Exhibit 4.1

AMENDMENT TO CONVERTIBLE NOTES

This AMENDMENT TO CONVERTIBLE NOTES (this “Amendment”) is made and entered into as of December 31, 2011 by and between Bohai Pharmaceuticals Group, Inc., a Nevada corporation (the “Company”), and Euro Pacific Capital, Inc. (the “Investor Representative”).

WHEREAS, on January 5, 2010, the Company consummated a $12,000,000 financing (the “Offering”) with certain accredited investors (the “Investors”) whereby the Company issued 6,000,000 units at $2.00 per unit, with each unit consisting of a $2.00 principal amount, two year convertible note (collectively, the “Notes”) and a three year common stock purchase warrant to purchase one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at $2.40 per share, subject to certain conditions (collectively, the “Warrants”);

WHEREAS, pursuant to Section 2.8 of that certain Securities Purchase Agreement, dated January 5, 2010, between the Company and the Investors (the “SPA”), each Investor duly appointed the Investor Representative as such Investor’s true and lawful agent and attorney-in-fact to, among other matters, waive any terms and conditions of the Notes and to be such Investor’s exclusive representative with respect to any matter, suit, claim, action or proceeding arising with respect to any transaction contemplated by the Notes and the Warrants (the “Power of Attorney”);

WHEREAS, the Company and the Investor Representative, exercising the Power of Attorney on behalf of the Investors, desire to modify certain provisions of the Notes on the terms set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and pursuant to the applicable provisions of the SPA and the Notes, the parties hereby amend the Notes as follows:

1.           Defined Terms.  All capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Notes.

2.           Amendments.  The Investor Representative and the Company hereby amend the Notes as follows:

(a)           The definition of “Maturity Date” contained in the Notes is hereby amended to extend such Maturity Date from January 5, 2012 (the two (2) year anniversary of the date of closing of the Minimum Amount) until April 5, 2012 (the period from January 5, 2012 to April 5, 2012 being referred to herein as the “Extended Period”).

 
1

 


(b)           In the event that all Principal and Interest on the Notes is not repaid in full by 5:00 p.m., New York City time, on January 5, 2012, then, during the Extended Period, Interest shall accrue on the unpaid Principal amount of the Notes at the rate of twelve percent (12%) per annum (or 3% for the Extended Period).

(c)           In the event that all Principal and Interest on the Notes is repaid in full prior to the conclusion of the Extended Period, Interest shall accrue on a pro rated basis through the date of repayment and not for the entire Extended Period.

3.           Ratification.  Except as expressly amended by this Amendment, the terms and conditions of the Notes are hereby confirmed and shall remain in full force and effect without impairment or modification.

4.           Power of Attorney.  The Investor Representative represents and warrants that it has not received any notice regarding and is not otherwise aware that any Investor has revoked or modified, or sought or desires to revoke or modify, the Power of Attorney with respect to such Investor or any Investor.  .

5.           Conflict.  In the event of any conflict between any Note and this Amendment, the terms of this Amendment shall govern.

6.           Binding Effect.  The parties acknowledge and agree that this Amendment complies with all of the applicable terms and conditions of the Notes that are necessary to effect an amendment to the Notes and therefore, upon the execution and delivery hereof by the parties, this Amendment shall have such binding effect.

7.           Governing Law; Venue.  All questions concerning the construction, validity, enforcement and interpretation of the this Amendment shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.  Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Amendment (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.  Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, New York for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of this Amendment), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper.  Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Amendment and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.  EACH PARTY HERETO (INCLUDING ITS AFFILIATES, AGENTS, OFFICERS, DIRECTORS AND EMPLOYEES) HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 
2

 



8.           Counterparts.  This Agreement may be executed in any number of counterparts and delivered by in email/.pdf format or by facsimile, each of which shall be deemed to be an original, and all of which taken together shall constitute one and the same instrument. 



[Signature Page Follows]

 
3

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered on their behalf as of the date first above written.
 
 
BOHAI PHARMACEUTICALS GROUP, INC.
 
       
 
By:
/s/ Hongwei Qu  
   
Name:  Hongwei Qu
Title:    CEO
 
       
       

 
EURO PACIFIC CAPITAL, INC., as Investor Representative
 
       
 
By:
/s/ Gordon McBean  
   
By:  /s/ Name:  Gordon McBean
Title:    President
 
       
       

 
 
4

 

EX-17 3 v243855_ex17-1.htm EXHIBIT 17.1 Unassociated Document
Letter of Resignation



To:  The Board of Directors
        Bohai Pharmaceuticals Group, Inc.
c/o Yantai Bohai Pharmaceuticals Group Co. Ltd.
No. 9 Daxin Road, Zhifu District
Yantai, Shandong Province, China 264000
 
 


December 31, 2011


Dear Sirs,

I, Gene Hsiao, hereby resign from the positions as Chief Financial Officer and Director of Bohai Pharmaceuticals Group, Inc. (the “Company”), with effect on the close of business on the date hereof.

I acknowledge and confirm that my resignation is not as a result of any disagreement with the Company on any matter relating to its operation, policies (including accounting or financial policies) or practices.  My decision to resign was difficult as working at the Company has been a great experience, for which I am extremely grateful.  I wish the Company every success in the future and thank Mr. Hongwei Qu for the opportunities I have been given during my tenure with the Company.



Yours faithfully,


/s/ Gene Hsiao
___________________
Gene Hsiao